The humanized anti-HER2 monoclonal antibody (mAb) Herceptin (trastuzumab) effectively inhibits HER2-positive breast tumors. However, many patients responding to treatment often develop resistance. Crosstalk between IGF-IR and HER2 and elevated IGF-IR signaling have been implicated in tumor cell resistance to Herceptin therapy. Previously, we reported that the anti-IGF-IR mAb m590 inhibits proliferation and migration of breast cancer MCF-7 cells in vitro.
Introduction
Human Epidermal Growth Factor Receptor 2 (HER2), encoded by the ErbB2 gene, is a member of the epidermal growth factor receptor (EGFR/ErbB) family (1) . HER2 is structurally similar to other EGFR family members, including HER1 (EGFR, ErbB1), HER3 (ErbB3), and HER4 (ErbB4), and also acts as a receptor tyrosine kinase. Homodimerization of HER1 and HER4 upon ligand binding activates intrinsic, intracellular protein-tyrosine kinase activity, resulting in receptor autophosphorylation and downstream signaling, including signaling pathways such as, the phosphatidylinositol 3-kinase (PI3K), the c-Jun NH(2)-terminal kinase (JNK), and the mitogen-activated protein kinase (MAPK), which promote DNA synthesis, cell proliferation and inhibition of cell apoptosis. HER3 does not have a tyrosine kinase domain, so it transfers signals upon ligand binding through heterodimerization with other EGFR family members that have kinase activity. Unlike HER1, HER3 and HER4, HER2 is unable to bind ligands and form homodimers. However, HER2 possesses tyrosine kinase activity, and appears to be the major signaling partner for EGFR family members through the formation of heteromeric complexes (2) . Heterodimerization between two EGFR family members requires ligand binding (3, 4) , but the crystal structure of a truncated HER2 ectodomain suggests that HER2 is constitutively in the activated conformation and readily interacts with HER3 mostly and other EGFR family members (5) . Overexpression of HER2 promotes ligand-independent formation of a HER2/HER3 receptor complex, a major oncogenic driver in HER2-overexpressing breast tumor cells (6) . Cleavage of HER2 by the extracellular protease, ADAM10, produces the HER2 ectodomain and a truncated, constitutively active HER2 receptor (p95HER2)
shown to drive carcinogenesis (7) . HER2 overexpression is associated with strong activation of the PI3K pathway, which stimulates cell proliferation by activating the protein kinase Akt and down-regulating the cyclin-dependent kinase (CDK) inhibitor, p27 (8) . HER2 can also activate the MAPK pathway via interaction with SHC and GRB2 adaptor proteins (9) . Overexpression of HER2 was found in breast and ovarian cancers, and associated with cancer metastasis (10) (11) (12) , poor clinical outcome and decreased survival rate (13) (14) (15) .
Type I Insulin-like Growth Factor Receptor (IGF-IR) is a tyrosine kinase receptor composed of 2 α subunits and 2 β subunits. Upon binding to either of the two ligands, Insulin-like growth factor I (IGF-I) or IGF-II, the extracellular domain of the α chains induces tyrosine autophosphorylation of the β chains in the cytoplasm. This activates the kinase activity of IGF-IR, and triggers downstream signaling via the PI3K/Akt and Ras/MAPK pathways, resulting in increased cell survival and cell proliferation (16, 17) . Elevated IGF-IR is found in many tumor malignancies, including breast, prostate and lung cancers (18, 19) . Additionally, overexpression of IGF-IR has been associated with disease progression and cancer metastasis (20, 21) .
HER2 is a widely used diagnostic marker and validated target for therapy. The humanized anti-HER2 mAb Herceptin (trastuzumab) has been effective in treating HER2-overexpressing breast cancers (22, 23) . Binding of Herceptin to HER2 causes internalization and degradation of the receptor in SKBR3 and MDA453 cells (24) . Herceptin binds to domain IV of the extracellular segment of HER2, leading to disruption of HER2/HER3 dimerization and ablation of downstream PI3K/Akt signalling (6) . Herceptin can also inhibit cleavage of HER2 ectodomain in breast cancer cells, thus block the generation of a constitutively active truncated receptor (p95HER2) (7, 25, 26) . In addition, Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) may partially contribute to the antitumor activity of Herceptin in vivo (27) .
Only 25-30% of breast cancer patients overexpress HER2, and patients treated with Herceptin can develop resistance as the disease progresses. Various mechanisms may account for this resistance, which likely involve the PI3K/Akt pathway, including elevated HER2-associated receptors and other receptors (28, 29) , cross activation between HER2 and other receptors (30) (31) (32) , blockage of Herceptin by membrane-associated glycoproteins such as mucin-4, removal of the Herceptin epitope by cleavage or loss of HER2 expression, and increased HER2 expression.
Accumulating evidence shows that crosstalk between HER2 and IGF-IR, including receptor heterodimerization and transactivation, and elevated IGF-IR signalling are associated with Herceptin resistance (31, (33) (34) (35) . Overexpression of IGF-IR in HER2-overexpressing breast cancer cell lines results in Herceptin resistance in vitro (36) . Inhibition of IGF-1R activity enhances the response to Herceptin in HER-2-positive breast cancer cells (37) . A phase II clinical trial of HER2-positive breast cancer patients revealed that overexpression of IGF-IR in the primary tumor was associated with resistance to Herceptin (38) . Therefore, co-targeting IGF-IR and HER2 may be clinically beneficial in minimizing the acquired resistance to Herceptin therapy.
We previously described a human/mouse chimeric mAb m590 that specifically bound with high affinity to IGF-IR and blocked the binding of IGF-I and IGF-II to IGF-IR. This inhibited ligand-induced phosphorylation of IGF-IR in breast cancer MCF-7 cells (39) . In this study, we generated a bispecific antibody (Bi-Ab) by engineering the m590 and Herceptin, and tested BiAb in vitro and in SKOV-3 HER2-and IGF-IR-overexpressing xenograft mouse model. We found that co-targeting HER2 and IGF-IR with Bi-Ab was more effective than targeting HER2 or IGF-IR alone with the monospecific antibodies or cotargeting HER2 and IGF-IR with a combination (Comb) of the two monospecific antibodies in ablating tumor cell proliferation in vitro and in vivo.
Materials and methods

Cell lines, antibodies and chemicals
Breast cancer MCF-7 cells were cultured in DMEM medium (Invitrogen) supplemented with 10% heat-inactivated FBS and 1% penicillin / streptomycin (P/S). Ovarian cancer SKOV-3 cells were cultured in McCoy's 5A medium (Hyclone) supplemented with 10% heat-inactivated FBS and 1% P/S. Both MCF-7 and SKOV-3 cell lines were obtained from National Cancer Institute, National Institutes of Health. No authentication was done by the authors. The following primary mAbs were purchased from Cell Signal Technology: rabbit anti-Phospho-AKT (Thr308) (C31E5E), rabbit anti-Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (D13.14.4E) XP, rabbit anti-Akt (pan) (11E7), rabbit anti-P44/42 MAPK (ERK1/2) (137F5), and rabbit anti-GAPDH mAb (14C10). The secondary antibodies were purchased from Jackson ImmunoResearch. Xenolight D-luciferin was purchased from Caliper Life Sciences.
Expression and purification of recombinant IGF-IR and HER2 ectodomains
The gene encoding the extracellular domain (ectodomain) of IGF-IR was amplified from the pBlueScript-IGF-IR construct P08069 (39) , and subcloned into the pSecTag2C vector at the EcoR I and Not I sites. The gene encoding HER2 ectodomain was amplified from SKOV-3 cell line by reverse transcriptase PCR, and subsequently cloned into the pSecTag2A vector at the Xho I and Sfi I sites. Both constructs were confirmed by DNA sequencing. Recombinant plasmid DNA. Recombinant antibodies were purified from the culture supernatants by Protein A (GE Healthcare) affinity purification.
Indirect ELISA
Recombinant ectodomains of IGF-IR or HER2 (2 μg/ml in both cases) were coated on 96-well high-binding ELISA plates at 4°C overnight. The plates were washed and blocked with 3% BSA in PBS at 37℃ for 2 h. Two-fold serially diluted mAb Herceptin or m590 were added to the wells and the bound mAbs were detected by HRP conjugated anti-human Fc as secondary antibody and TMB substrate. Optical density at 450 nm (OD450nm) was measured after color development at RT for 30 min. In the case of Bi-Ab, recombinant IGF-IR ectodomains were coated on the plates. Following addition of 2-fold serially diluted antibodies and incubation at RT for 2 h, plates were washed and biotinylated HER2 ectodomain (2 μg/ml) was added to each well. Bound HER2 ectodomains were detected by HRP conjugated streptavidin and TMB substrate.
Western blotting
MCF-7 or SKOV-3 cells in complete medium were seeded in 6-well plates. When cells reached 70-80% confluence, they were incubated in serum-free medium overnight. Cells were treated with antibodies for 30 min, followed by addition of 1.5 nM IGF-I and further incubation for 30 min. Cells were then lysed and 10 μl of cell lysates from each sample was resolved by 12% SDS-PAGE. Once the proteins were transferred, PVDF membranes were blocked with 5% skim milk in PBS for 30 min, incubated with primary antibodies, and then secondary antibodies.
The membranes were extensively washed after each incubation step. The Western blot signal was detected by Western Bright ECL-HRP substrate (Advansta).
Flow cytometry
MCF-7 or SKOV-3 cells were detached using enzyme-free cell-disassociation buffer (Invitrogen), washed twice with PBS, and incubated at 4°C for 2 h with antibodies in fluorescence-activated cell sorting (FACS) buffer (1% FBS in PBS). Cell surface bound antibodies were detected using PE conjugated to anti-human Fc by incubation at 4°C for 1 h followed by washing twice with FACS buffer and fixation with 2% paraformaldehyde in FACS buffer. The stained cells were analyzed with a BD flow cytometer and FlowJo software.
ADCC assay
The flow cytometry-based ADCC assay has been described previously (40) . Here, we used D-luciferin (100 μl) at a concentration of 30 mg/ml in DPBS (5 μl/g body weight) was then injected intra-peritoneally (i.p.) into each mouse (each mouse received 300 mg luciferin/kg body weight). About 15 min post injection, mice were imaged for luminescence intensity in the regions of interest (ROI) using Xenogen IVIS 100 in vivo imaging system. Mice were then randomized, so that each group of mice had approximately the same average luminescence intensity. Each group had 7 mice and a total of 4 groups were formed corresponding to Herceptin, m590, Bi-Ab, and Comb treatment conditions. Each antibody (100 μg) or antibody combination (100 μg total) were injected by i.p. into each mouse on days 1, 4, 6 and 8. 
Results
Bi-Ab co-targets IGF-IR and HER2
We used the "knobs-into-holes" approach to generate an anti-IGF-IR/anti-HER2 hybrid IgG (41) (42) (43) . A "knob" mutant was created by replacing a Threonine with Tyrosine (T366Y) in the CH3 domain of Herceptin. A "hole" mutant was made by replacing a Tyrosine with Threonine (Y407T) in the CH3 domain of m590. Co-transfection of 293F cells with the "knob" and "hole" plasmids resulted in the production of stable heterodimers that exhibited bispecificity for both HER2 and IGF-IR (Fig. 1) . The bispecific antibody (Bi-Ab) bound to recombinant IGF-IR and HER2 ectodomains (Fig. 1C) and to overexpressed, membrane-associated IGF-IR and HER2 on SKOV-3 cells (Fig. 1B and 1D ). Compared to breast cancer MCF-7 cells used in our previous study, ovarian cancer SKOV-3 cells express a high level of HER2 and a modest level of IGF-IR (Fig. 1A) . Similar to the two parental antibodies, m590 and Herceptin, Bi-Ab bound to SKOV-3 in a dose-dependent manner (Fig. 1D) . Moreover, flow cytometry analysis revealed that Herceptin and Bi-Ab have a similar binding profile which shows two peaks in the histogram ( 
Bi-Ab inhibits receptor phosphorylation and down-regulates downstream PI3K/Akt and MAPK signaling
We previously reported that m590 blocked ligand-induced IGF-IR phosphorylation in breast cancer MCF-7 cells (39), and inhibited MCF-7 cell proliferation and migration (44) . We extended these findings in this study by analyzing the downstream signaling of IGF-IR. We found that m590 inhibited ligand-induced phosphorylation of Akt and ERK in MCF-7 cells ( Fig.   2A ), and synergized with Herceptin in inhibiting ligand-induced Akt phosphorylation in MCF-7 cells (Fig. 2B) . Next, we then compared the effects of Bi-Ab, m590 and Herceptin on phosphorylation of IGF-IR in SKOV-3 cells (Fig. 2C ) and downstream signaling in MCF-7 ( Fig.   2D ) and SKOV-3 cells (Fig. 2E ) in the presence of ligand (IGF-I) or absence of ligand (Fig. 2F) . (Fig. 2C) . In MCF-7 cells, m590 and Bi-Ab, as well as Comb inhibited ligand-induced phosphorylation of Akt, but only Bi-Ab inhibited ligandinduced phosphorylation of ERK (Fig. 2D) . Treatment with Herceptin slightly enhanced ligandinduced phosphorylation of Akt in MCF-7 cells (Fig. 2D, lane 2) . None of the antibodies showed inhibitory effects on ligand-induced phosphorylation of Akt and ERK in SKOV3 cells at the antibody concentration (100 μg/ml) tested (Fig. 2E) . When we compared the effects of Bi-Ab, m590 and Herceptin on phosphorylation of ERK in MCF-7 and SKOV-3 cells (Fig. 2F ) in the absence of ligand, we found that in MCF-7 cells, both m590 and Bi-Ab inhibited ERK phosphorylation, and Comb treatment slightly reduced ERK phosphorylation (data not shown), but in SKOV-3 cells, Bi-Ab inhibited ERK phosphorylation (Fig. 2F) , and this inhibition was dose-dependent ( (Fig. 2D ), but Bi-Ab was more effective than m590 and Comb in inhibiting ligand-induced ERK phosphorylation in MCF-7 cells (Fig. 2D) , and more effective than Comb in inhibiting ERK phosphorylation in SKOV-3 cells in the absence of ligand (Fig. 2F) . (Fig. 3A) . Notably, although Comb treatment showed enhanced inhibition of SKOV-3 proliferation compared with Herceptin treatment alone, both treatment conditions were significantly less potent than Bi-Ab, especially at high antibody concentrations (over 25 μg/ml) (Fig. 3A) . M590 inhibited SKOV-3 cell proliferation, but its effect decreased sharply as m590 concentration decreased (Fig. 3A) .
Bi-Ab more effectively inhibits cancer cell proliferation than
To investigate whether "knob" and "hole" mutations affected Fc-mediated effector function, we tested Bi-Ab for ADCC activity in a flow cytometry based assay using SKOV-3 as target activity comparable to or slightly higher than that of m590, Herceptin, and the combination of m590 and Herceptin (Comb) (Fig. 3B) . Notably, percent ADCC with Bi-Ab was significantly higher than that with Comb at 1 μg/ml (P-value < 0.05). These results suggest Bi-Ab remains effective in killing HER2-and / or IGF-IR-overexpressing tumor cells through ADCC in vivo.
Bi-Ab inhibits tumor growth in SKOV-3 HER2-and IGF-IR-overexpressing xenograft mouse model
To establish a HER2-and IGF-IR-overexpressing cancer xenograft mouse model for testing the effect of Bi-Ab in vivo, we generated a SKOV-3-Luc stable cell line expressing luciferase.
We tested Bi-Ab, m590, Herceptin, and Comb in this mouse model following the protocol shown The average luminescence intensities varied across all the experimental groups (Fig. 4B) . significantly lower average luminescence intensities than the m590 group (P-value < 0.001) from day 6 to day 35, the end of the mouse study, while the Comb group only showed significantly lower average luminescence intensities than the m590 group on days 6, 8, and 11, and the Herceptin group only showed significant lower average luminescence intensities than the m590 group on days 8 and 11 (Fig. 5A) . The average luminescence intensity of the m590 group also decreased on day 11, and further decreased on day 15, but returned to high levels on days 25 and 35. These decreases may not be caused by m590 treatment because the control group also showed slightly decreases in average luminescence intensity on day 11 and 15 ( Fig. 4B) . The Comb group showed relapse (increased average luminescence intensity) starting on day 25, while the Herceptin group relapsed earlier on day 15. The average luminescence intensity of the Bi-Ab on day 35 slightly increased, but it was still significantly lower than that of the m590 group (Fig. 5A ).
We then investigated individual mouse in each group and counted the number of mouse that had 2-fold higher luminescence intensity than the baseline level (no inoculation) (Fig. 5B) . The Bi-Ab group showed early decrease in luminescence intensity. 5 out 7 mice in the Bi-Ab group had luminescence intensities below 2-fold of the baseline level on day 4, while only 3 out 7 mice in the Comb and Herceptin groups had the same low levels of luminescence intensity on day 4 (Fig. 5B) . The rest 2 mice in the Bi-Ab showed luminescence intensities below 2-fold of the baseline level on days 8 and 15, and the luminescence intensities of all mice in the Bi-Ab group remained low till the end of the mouse study except that one mouse relapsed on day 35 (Fig. 5B) . on day 8, but these mice relapsed one by one as the study progressed. There was only one mouse left in the Herceptin group that had the luminescence intensity below 2-fold of the baseline level on day 35 (Fig. 5B) . None of mice in the m590 ever exhibited luminescence intensity below 2-fold of the baseline level throughout the study. These results indicate that dual targeting HER2
and IGF-IR is more effective than single targeting in inhibiting HER2-and IGF-IRoverexpressing tumor growth and postponing tumor relapse in vivo, and Bi-Ab more effectively inhibits tumor growth and prevents tumor relapse than simple combination of two monospecific antibodies.
Discussion
Breast cancer is one of the most common cancers in women. It accounts for 22.9% of all cancer cases in women worldwide and was responsible for 13.7% of cancer deaths in 2008.
EGFR and IGF-IR activation contributes to the initiation and progression of breast cancer.
Herceptin (trastuzumab) has been in clinical use for treatment of HER2-overexpressing breast cancers, but patients often develop resistance to the therapy. Thus, there is a need for novel therapies. In this study, we generated and tested Bi-Ab, a "knobs-into-holes" bispecific antibody This study was promoted by our observation that m590 synergized with Herceptin in inhibiting Akt phosphorylation in MCF-7 cells (Fig 2B) . But when we come to SKOV-3 cell line that expresses much higher level of HER2 than MCF-7, the inhibition of Akt and ERK (6) . ERK kinase can phosphorylate dual specific phosphatases Cdc25c. Down-regulated ERK phosphorylation reduces the activity of Cdc25c, resulting in increased phosphorylation of receptor tyrosine kinase (RTK), such as IGF-IR. Therefore, although the MAPK pathway is blocked by Herceptin, following the activation of IGF-IR, the PI3K/Akt pathway is triggered, leading to a compensatory effect, which rescues tumor cells from apoptosis. This feedback loop was first reported by Prahallad et al. in 2012 (45) . We observed the same phenomenon in this study ( Fig. 2D-2F ). The increased Akt phosphorylation caused by the feedback loop makes anti-IGF-IR mAb m590 less effective in inhibiting Akt phosphorylation, especially in the presence of IGF-I (Fig 2E and 2F) . Nevertheless, m590 and Bi-Ab inhibit ligand-induced phosphorylation of IGF-IR in SKOV-3 cells (Fig. 2F) , and Bi-Ab inhibits ERK phosphorylation in a dose-dependent manner in SKOV-3 cells in the absence of IGF-I (Fig. 2G) 
Different methodologies have been described to generate bispecific antibodies by design (42, 46) . We took advantage of the "knobs-into-holes" strategy for generating Bi-Ab (42) . Cotransfection of 293F cells with the "knob" and "hole" mutant plasmids yielded Bi-Ab. Protein A affinity-purified Bi-Ab showed a single peak in gel filtration (data not shown). More importantly, "knobs-into-holes" mutations located in the CH3 domain did not affect antibody effector functions which are mediated mainly by the CH2 domain of antibodies as evidenced by the high ADCC activity of Bi-Ab. ADCC is an important mechanism of action for therapeutic antibodies in vivo (47) (48) (49) . The result from our ADCC assay demonstrates that Bi-Ab has comparable or slightly enhanced ADCC activity compared with monospecific antibodies, m590 and Herceptin, and the Comb. Notably, this is the first report showing that the "knobs-into-holes" strategy did done to test if there was significant difference in percent ADCC between any two antibodies at the same concentration. Percent ADCC between Bi-Ab and Comb at 1 μg/ml showed significant difference (P-value < 0.05), which is indicated. Each antibody dilution was tested in triplicate and the assays were repeated once. 
